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ABSTRACT 
Simple, sensitive, rapid and accurate UV spectroscopic methods have been developed for the estimation of metformin hydrochloride and 
pioglitazone in tablet dosage forms. Simultaneous estimation and dual-wavelength methods were developed and validated using solvent 
methanol. Both drugs show linearity at 5-40 µg/ml for both methods. The suggested techniques have been effectively implemented in 
pharmaceutical formulations to the evaluation of quoted drugs. Recovery research was conducted to verify the method's accuracy, precision. 
The techniques have been validated under ICH guidelines. 
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INTRODUCTION: 
Piomar 7.5-MF tablets contain two oral anti-hyperglycemic 
drugs that contain metformin hydrochloride and 
Pioglitazone. Metformin Hydrochloride is a biguanide class 
of antidiabetic drug. Chemically, metformin hydrochloride is 
a (N, N-dimethyl Imidodicarbonimidic diamide 
monohydrochloride) as shown in Figure 1. 
 
Figure 1. Metformin hydrochloride 
Metformin hydrochloride used to treat diabetes mellitus–II. 
It decreases the glucose absorption in the small intestine, 
increases glucose transport into cells, decreases the plasma 
frees fatty acid concentrations and inhibits gluconeogenesis. 
Activation of AMPK plays a vital role in these processes. It 
improves hepatic and peripheral issue sensitivity to insulin 
without the problem of series lactic acidosis. Metformin 
hydrochloride is official in BP, Martindale and Merck Index.  
Pioglitazone is an oral antihyperglycemic agent that mainly 
operates by reducing resistance to insulin. Chemically 
specified as (±)-5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy] 
methyl]-2, 4-thiazolidinedione as shown in figure 2. 
Molecular formula and molecular weight are C19H20N2O3S 
and 356.44g/mol respectively. It is not official in any 
pharmacopeia. It has been used together in combination to 
achieve better glycolic control and patient compliance. This 
paper aimed to explore the possibility of using techniques of 
simultaneous estimation method and dual-wavelength 
methods for quantifying metformin hydrochloride and 
pioglitazone simultaneously in their mixture form. The 
advantage of these proposed methods is that no separation 
is required. The proposed procedures are simple, rapid and 
act as a convenient alternative to the HPLC method. 
 
Figure 2. Pioglitazone 
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Literature survey revealed that reports on analytical 
methods such as UV-Visible, HPLC, LC-MS, LC-MS/MS and 
HPTLC for the determination of metformin hydrochloride 
and pioglitazone from the bulk and dosage form, very few 
analytical methods reported for metformin hydrochloride 
and pioglitazone. The present investigation was carried out 
in the view of establishing a simple, rapid, accurate, 
economical, precise and robust UV method for estimation 
metformin hydrochloride and pioglitazone in bulk and tablet 
dosage form using methanol as the solvent. 
METHOD DEVELOPMENT: 
PREPARATION OF STANDARD STOCK SOLUTION: 
Standard metformin hydrochloride stock solution 
(100µg/ml):  
Accurately weighed metformin hydrochloride (10mg) was 
transferred to a 100ml volumetric flask. Dissolved it in 
methanol and make up the volume with the same. Dilutions 
from stock solution were prepared in the range of 5-40 
μg/ml. 
Standard pioglitazone stock solution (100µg/ml): 
Accurately weighed pioglitazone (10mg) was transferred to 
a 100ml volumetric flask and dissolved in methanol to the 
mark with methanol. Dilutions from stock solution were 
prepared in the range of 5-40 μg/ml.  
Methanol was used as a blank solution.  
METHOD A: SIMULTANEOUS DETERMINATION 
The standard solutions of metformin hydrochloride and 
pioglitazone were scanned separately in the range of 200 to 
400 nm against methanol as blank and wavelengths of 
maximum absorbance were determined. The concentrations 
of drugs were determined using the following equations: 
   
 A2  ay1 – A1 ay2 
 ax2 ay1 – ax1 ay2 
   ---------- Equation no. 1 
   
 A1  ax2 – A2 ax1  
 ax2 ay1 – ax1 ay2  
  ---------- Equation no. 2 
Where,  
Cx = Concentration of metformin hydrochloride in gm/lit  
Cy = Concentration of pioglitazone in gm/lit  
A2 =Absorbance of sample solution at 225.4nm  
A1 =Absorbance of sample solution at 237.4nm  
ax1= absorptivity of metformin hydrochloride at 237.4 nm  
ay1= absorptivity of pioglitazone at 237.4nm  
ax2= absorptivity of metformin hydrochloride at 225.4 nm  
ay2= absorptivity of pioglitazone at 225.4nm 
 
 
Figure 3. Calibration Curve of Metformin Hydrochloride 
 
 
Figure 4. Calibration Curve for Pioglitazone 
 
Figure 5. Overlain Spectra of Metformin Hydrochloride and 
Pioglitazone 
METHOD B: DUAL WAVELENGTH METHOD 
In this method, two wavelengths were selected for each drug 
in a way so that the difference in absorption is zero for one 
drug at a time. As per the spectrum, we found that the 
absorption of metformin hydrochloride was the same at 
232.4nm and 241.8nm so that these wavelengths were 
selected for the estimation of pioglitazone and same as in 
264.8nm and 272.8nm absorption of pioglitazone were same 
hence these two wavelengths were selected for estimation of 
metformin hydrochloride. At these selected wavelengths, all 
the mixed standard was scanned and a calibration curve 
between the absorbance difference and the respective 
concentrations was plotted. The value of the coefficient of 
correlation was 0.993 and 0.996 for metformin 
hydrochloride and pioglitazone respectively. The sample 
solutions were evaluated at chosen wavelengths and to 
obtain the concentration values of variation in absorption 
were extrapolated to the working standard curve.  
 
 
Figure 8 Calibration Curve for Metformin Hydrochloride 
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Figure 9 Calibration Curve for Pioglitazone 
ANALYSIS OF TABLET DOSAGE FORMS ANALYSIS OF 
TABLET FORMULATIONS  
For the estimation of drugs from the tablet dosage form, 
twenty tablets of metformin hydrochloride and pioglitazone 
in combination were weighed accurately and the average 
weight per tablet was calculated. Tablets were ground to a 
fine powder a quantity equivalent to 10mg of metformin 
hydrochloride and 0.15mg of pioglitazone was transferred to 
a volumetric flask and was extracted with 100ml of 
methanol. The extract was filtered using Whatman filter 
paper, and the filtrate was approximately diluted to get a 
final concentration for both metformin hydrochloride and 
pioglitazone. The solution was further diluted to get a final 
concentration of 20µg/ml of the formulation. The 
absorbance of the solution was measured at their maximum 
wavelength. 
The values of the absorptions were substituted in the 
respective formulas (Equation no.1 & 2) to obtain the 
content of metformin hydrochloride and pioglitazone. In the 
dual-wavelength method, the sample solution was scanned 
at 232.4nm and 241.8nm for pioglitazone while 264.8nm 
and 272.8nm for metformin hydrochloride. The 
concentration of metformin hydrochloride and pioglitazone 
was determined from their calibration curve plotted 
between absorption difference and concentration.   The 
results of the analysis are given in Table 1. 
VALIDATION:  
The method was developed and validated according to the 
analytical procedure as per the ICH guidelines for validation 
of analytical procedures to determine linearity, accuracy, 
precision, ruggedness, and robustness for the analytes i.e. 
metformin hydrochloride and pioglitazone. 
Linearity:  
An analytical method's linearity is its ability to produce test 
results that are proportional to the concentration of the 
analytes within a given range in samples. The linearity of 
measurement was evaluated by analyzing different 
concentration of the standard solution of metformin 
hydrochloride and pioglitazone. Calibration curves were 
built and the suggested technique was assessed in the 
respective statistical study by its correlation coefficient and 
intercept value calculated. For both the method, the Beer-
Lambert’s concentration range was found to be 5-40 μg/ml. 
Precision: 
An analytical procedure's accuracy reflects the proximity of 
agreement (degree of scattering) between sequences of 
measurements acquired under the prescribed circumstances 
from the various sampling of the same homogeneous 
sample. 
Precision can be taken into account at three levels: 
repeatability, intermediate (intraday) precision and 
reproducibility (interday precision). 
1] Intraday Precision: 
Solutions containing 10, 15, 20 μg/ml of Metformin HCl and 
10, 15, 20 μg/ml of Pioglitazone were analyzed three times 
on the same day and %R.S.D was calculated. 
2] Interday Precision: 
Solutions containing 10, 15, 20 μg/ml of Metformin HCl and 
10, 15, 20 μg/ml of Pioglitazone were analyzed on three 
different successive days and %R.S.D was calculated. 
3] Repeatability: 
Method precision of the experiment was performed by 
preparing the standard solution of Metformin HCl (15 
μg/ml  and Pioglitazone  15μg/ml  for six times and 
analyzed as per the proposed method.  
Limit of Detection (LOD): 
The detection limit can be calculated using the following 
equation in accordance with ICH rules. 
LOD = 3.3 x (N / S) 
Where, N = Standard deviation of the drug's peak areas  
             S = Slope of the respective calibration curve. 
Limit of Quantification (LOQ): 
The quantification limit can be calculated using the following 
equation in accordance with ICH rules. 
LOQ = 10 x (N / S) 
Where, N = Standard deviation of the drug's peak areas  
             S = Slope of the respective calibration curve.
 
Table no.1 Optical Characteristics and Validation Study of Formulation 
Parameters Method A Method B 
Metformin HCl Pioglitazone Metformin HCl Pioglitazone 
Wavelength λ max  nm  237.4 225.4 264.8 and 272.8 232.4 and 272.8 
Beer’s law limit  µg/ml  5-40 5-40 5-40 5-40 
Correlation coefficient (R2) 0.993 0.994 0.9936 0.9969 
Slope  0.057 0.041 0.001 0.03 
Intercept  0.009 0.029 0.0019 0.01 
SD 0.698 0.507 0.0172 0.365 
RSD 54.06 54.03 60.33 53.15 
Precision 
1. Interday (% RSD) 
Intraday (% RSD) 
 
0.081 
0.167 
 
0.156 
0.20 
 
0.49 
0.54 
 
0.202 
0.22 
LOD (µg/ml) 40.41 40.80 56.76 40.15 
LOQ (µg/ml) 122.45 123.65 172 121.66 
y = 0.03x + 0.010 
R² = 0.9969 
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Table No. 2 Tablet Analysis Data for Both Methods 
Method Drugs Label claim Amount recovered % Recovery 
A 1. Metformin hydrochloride 
2. Pioglitazone 
500 
7.5 
501 
7.45 
100.2 
99.33 
b 1. Metformin hydrochloride 
2. Pioglitazone 
500 
7.5 
497.5 
7.4 
99.5 
98.66 
 
RESULT AND DISCUSSION:  
Simple, precise and accurate simultaneous equation and 
dual-wavelength methods were developed for the 
simultaneous estimation of metformin hydrochloride and 
pioglitazone in combined dosage forms. The wavelengths 
used for the simultaneous equation were 225.4 nm and 
237.4 nm; and for dual-wavelength method, it was 232.4 nm, 
241.8 nm, 264.8nm and 272.8nm. Beer’s law obeyed in a 
concentration range of 5-40 µg/mL for both metformin 
hydrochloride and pioglitazone for both the methods. The 
absorptivity and absorbance were determined and the 
values were substituted in the equation to obtain the results. 
Two commercial formulations containing metformin 
hydrochloride and pioglitazone were analyzed by the 
proposed method. The percentage relative standard 
deviation for precision and accuracy was found to be low, 
which indicates that the method has considerable accuracy 
and precision.  
Standard calibration curves of metformin hydrochloride and 
pioglitazone for method II were linear with correlation 
coefficient (R2), slope and intercept 0.993, 0.001 and - 
0.001; 0.996, 0.03 and  0.01 respectively. Recovery greater 
than 98.6% with the low standard deviation justifies the 
accuracy of the method. The results are in good agreement 
with the label claim. The suggested technique is discovered 
to be easy, precise, accurate and delicate and can, therefore, 
be used as a quality control instrument to simultaneously 
estimate both drugs in the quality control laboratory from 
their mixed dosage form. 
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